Medherant, a University of Warwick spin-out company, developing transdermal drug delivery patch technology, has announced the appointment of Sheryl Caswell as head of clinical development.
New job
This appointment comes as the company prepares the commencement of clinical studies with its ibuprofen patch that has been developed using the TEPI Patch technology.
“We’re delighted that Sheryl will be joining us at such an important time in the company’s development,” said Nigel Davis, CEO of Medherant. “Sheryl has over 20 years’ experience leading clinical development programmes on a wide range of products including other ibuprofen products.”
The ibuprofen patch developed with the TEPI Patch technology has been designed to enable controlled release of the pain killer for a 24-hour period. It is hoped that this technology will enable more drugs to be administered through the skin, including those that are unsuitable for oral administration.
“I am delighted to join Medherant to lead clinical development at this exciting time and look forward to initiation of the company’s first clinical study,” Caswell commented. “I believe the TEPI Patch technology developed by Medherant will provide patients with a much-needed convenient dosing form for a wide range of drugs.”
